351 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1900)
- Addiction (16)
- Allergy, Asthma, & Immunology (12)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (28)
- Blood Disorders (38)
- Bone & Muscle (10)
- Cancer
(726)
- Bladder Cancer (14)
- Brain Cancer (25)
- Breast Cancer (70)
- Gastrointestinal (16)
- Gynecologic Cancer (28)
- Head and Neck Cancer (4)
- Kidney Cancer (8)
- Leukemia (75)
- Liver Cancer (10)
- Lung Cancer (62)
- (-) Lymphoma (45)
- Multiple Myeloma (30)
- Pancreatic Cancer (22)
- Prostate Cancer (36)
- Sarcoma (25)
- Skin Cancer (30)
- Solid Tumors (42)
- Thyroid Cancer (1)
- Uveal Melanoma (7)
- Child Development (4)
- COVID-19 (Coronavirus) (37)
- Critical Illness (1)
- Dental (2)
- Developmental Disorders (2)
- Diabetes (22)
- Ear, Nose and Throat (11)
- Endocrine & Metabolic Disease (13)
- Eye (8)
- Gastrointestinal and Digestive Diseases (22)
- Hair and Skin Disorders (2)
- Headaches (5)
- Healthy Volunteers (175)
- Heart Disease (128)
- (-) Infectious Disease (48)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (48)
- Lung Disease (32)
- Meniere's Disease (1)
- Neurological Disorders (174)
- Nutrition (4)
- Obesity (9)
- Obstetrics & Gynecology (51)
- Pain Management (1)
- Pediatrics (104)
- Psychiatric Disorders (65)
- Rehabilitation (8)
- Stroke (7)
- Surgery (7)
- Transplant (51)
- Urology (4)
- Vascular Conditions (9)
Displaying 1 - 106 of 106
Condition: Infectious Disease / Lyme Disease
Investigator: Brian Fallon, MD
Status: Currently Recruiting
Are you suffering from persistent symptoms that began after you were diagnosed and treated with antibiotics for Lyme Disease? This new research study aims to test a new form of treatment for people with persistent symptoms despite antibiotic treatment for Lyme disease. This treatment involves stimulating a nerve on the surface of your ear. This is called…
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Currently Recruiting
This trial is testing an experimental treatment for HIV that is called CAB + RPV LA (long-acting cabotegravir and rilpivirine). CAB + RPV LA is a combination of drugs that is used to treat HIV (called antiretroviral therapy ART). It is currently approved in the US for the treatment of people living with HIV who are taking ART and whose viral load is already…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Currently Recruiting
The purpose of this study is to compare the usual treatment alone to using duvelisib or CC-486 plus the usual treatment for patients with peripheral T-cell lymphoma. The usual approach for patients who are not in a study is treatment with the FDA-approved chemotherapy regimens used in this trial (CHOP or CHOEP) without the addition of the study drugs…
Condition: Cancer / Lymphoma
Investigator: Hua-Jay Cherng, MD
Status: Currently Recruiting
This research study is studying the phased variant enrichment and detection sequencing (PhasED-seq) circulating tumor DNA (ctDNA) assay in diffuse large B-cell lymphoma (DLBCL). The PhasED-seq assay is a blood test to measure tiny fragments of material released into the blood by lymphoma called circulating tumor DNA. The purpose of this study is to 1)…
Condition: Cancer / Lymphoma
Investigator: Hua-Jay Cherng, MD
Status: Currently Recruiting
Can we lower the chance of Diffuse Large B-cell Lymphoma (DLBCL) cancer growing or spreading by adding treatment to the usual therapy? This study is being done to find out if this approach is better or worse than the usual approach for DLBCL patients receiving chimeric antigen receptor (CAR) T-cell therapy. The usual approach for Relapsed/Refractory DLBCL…
Condition: Cancer / Lymphoma
Investigator: Divaya Bhutani, MD
Status: Currently Recruiting
The purpose of this study is to see if Isatuximab can alter the immune system favorably in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. This study will have two arms. On one arm (control arm), Participants will receive standard transplant procedures and on the other arm (experimental arm),…
Condition: Cancer / Lymphoma
Investigator: Barbara Pro, MD
Status: Currently Recruiting
The purpose of this study is to see what effects, good and/or bad, the study drug, ST-001, has on you and your cancer, to find the best dose for treating your condition, and to see how safe ST-001 is for participants with your condition. This study will help us understand more about whether intravenous (injected into the vein) ST-001, will be a useful study…
Condition: Infectious Disease / Lyme Disease
Investigator: Brian Fallon, MD
Status: Currently Recruiting
Have you been treated for Lyme Disease but continue to have brain fog or other cognitive problems? This research study will assess a non-medication non-invasive intervention to improve cognitive functioning in people with persistent cognitive problems despite prior antibiotic treatment for Lyme Disease. Participants will complete this 4 week intervention at…
Condition: Infectious Disease / Lyme Disease
Investigator: Brian Fallon, MD
Status: Currently Recruiting
This patient case registry for Lyme and other Tick-borne Diseases is a component of the Clinical Trials Network that was launched in 2021 by a grant from the Steven and Alexandra Cohen Foundation. The registry will gather general information such as demographics, medical history, and current functional status. This information will help researchers to…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Currently Recruiting
This study is being done to determine if a study drug called lenalidomide can be combined with full doses of EPOCH chemotherapy for patients with Adult T-Cell Leukemia-Lymphoma (ATLL), and to define the highest dose and longest duration of lenalidomide that can be given safely in combination with EPOCH. EPOCH chemotherapy is a combination of five…
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Currently Recruiting
The HIV Vaccine Trials Network (HVTN), Division of AIDS (DAIDS), and Columbia University Irving Medical Center (CUIMC) are conducting a trial to learn about the safety and effectiveness of a new experimental HIV vaccine. The goal is to understand if the study products are safe to use in people living with HIV, and whether they can get the study products…
Condition: Infectious Disease / HIV
Investigator: Yael Hirsch-Moverman, PhD
Status: Currently Recruiting
HPTN 102/ PURPOSE 3 is a clinical study being done with cisgender women in the US to see whether an investigational twice-a-year (every 6 months) injection medicine can help reduce the risk of getting HIV from sex. The safety and efficacy of the medicine, which is called lenacapavir (LEN), is being studied for the prevention of HIV as pre-exposure…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Currently Recruiting
The purpose of this study is to test the safety of drugs called tazemetostat and belinostat when administered together. This study tests different doses of the drugs to see which doses are safer for people. There will be between 21 and 48 people taking part in this study. There are two parts in this study, a dose escalation (dose finding) part and a dose…
Condition: Blood Disorders / Amyloidosis
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
The purpose of this study is to see how safe and effective is the study drug, ABBV-383. ABBV-383 works by binding to a specific protein called B-cell maturation antigen, which is found on the surface of cells affected by amyloidosis. By engaging T-cells, a type of white blood cell, ABBV-383 helps activate the immune response to target and remove the…
Condition: Cancer / Lymphoma
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This study will utilize an investigational drug combination (also known as the study drugs) called relatlimab and nivolumab as a possible treatment for recurrent/relapsed (returned) or refractory (treatment-resistant) cHL and NHL. An investigational drug combination is one that has not been approved by regulatory agencies, such as the United States (US)…
Condition: Infectious Disease / HIV
Investigator: Marcus Pereira, MD, MPH
Status: Currently Recruiting
The primary objective is to evaluate long-term outcomes in transplant recipients with HIV who receive livers from donors with HIV compared to donors without HIV. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).
Condition: Infectious Disease / HIV
Investigator: Marcus Pereira, MD, MPH
Status: Currently Recruiting
The primary objective is to determine whether using hearts from HIV+ donors for HIV+ recipients is safe with regard to major transplant-related and HIV-related complications. The primary outcome is patient survival at one year. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).
Condition: Cancer / Lymphoma
Investigator: Barbara Pro, MD
Status: Currently Recruiting
The purpose of this study is to find out the safety, effectiveness, and blood levels of various doses of the study drug in participants with T-cell lymphoma that has not improved or has gotten worse. ONO-4685 is an experimental drug which is not approved by Health Authorities including the United States Food and Drug Administration (FDA). The study drug is…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Currently Recruiting
The purpose of this study is to find out if the experimental products, KITE-363 and KITE-753, are safe and effective in treating relapsed and/or refractory B-cell lymphoma. Participants will receive either KITE-363 or KITE-753 one time through intravenous (IV) infusion. The experimental treatment would involve removing some of your immune cells, genetically…
Condition: Infectious Disease
Investigator: Yael Hirsch-Moverman, PhD
Status: Currently Recruiting
ICAP/Harlem Prevention Center has been working to develop medications and strategies to help prevent HIV and other STIs since 2009. We are always looking for volunteers to participate in this research. Currently, we are looking for sexually-active individuals 18 years or older who are interested in learning more about our HIV and STI prevention research…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Currently Recruiting
The purpose of this study is to find out if the experimental product, axi-cel, is safe and effective in treating your lymphoma, compared to standard of care (SOC) therapy (chemotherapy), which includes either R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone) or DA EPOCH R (dose-adjusted etoposide, prednisone, vincristine,…
Condition: Infectious Disease / HIV
Investigator: Rebecca Schnall, PhD, RN
Status: Currently Recruiting
****The WiseApp in Spanish Study is looking for Spanish-speaking People Living with HIV Residing in the NYC Area**** Are you living with HIV? Are you 18 years or older? Are you a Spanish speaker? Do you own a smartphone? Are you interested in learning more about your health? We are conducting a study at Columbia University School of Nursing to learn more…
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Currently Recruiting
Do you identify as a woman or transgender person, or do you have a non-binary gender identity? Has a medical provider ever diagnosed you with a sexually transmitted infection or recommended PrEP/another HIV prevention method? We are conducting a study to understand attitudes and preferences regarding HIV prevention methods among people who do not have HIV.…
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Currently Recruiting
We are looking for individuals 18 to 60 years old who are interested in learning more about HIV prevention and biomedical research studies. We will ask you to complete a brief questionnaire to find out if we can schedule you for a one-on-one, 1.5-hour education visit to learn about the research we do. The education visit will help you decide if you want to…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Closed
This study is being done to answer the following questions: Will patients that are 75 years of age or older who were recently diagnosed with Diffuse Large B Cell Lymphoma (DLBCL) be able to take the study drug CC-486 (oral azacitidine) plus the standard drug therapy that fights cancer cells for at least 4 cycles of therapy (a cycle = 21 days; 4 cycles is 12…
Condition: Blood Disorders / Amyloidosis
Investigator: Rajshekhar Chakraborty, MD
Status: Closed
The purpose of this study is to evaluate whether birtamimab plus standard of care will improve survival in subjects with Mayo Stage IV AL amyloidosis. Birtamimab has not yet been approved by the Food and Drug Administration (FDA). During the first phase of the study, the purpose of this study is to evaluate whether birtamimab plus standard of care will…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Closed
The purpose of the study is to evaluate the safety and tolerability of tazemetostat in combination with lenalidomide + rituximab in patients with follicular lymphoma that has returned or has not responded to treatment (relapsed/refractory). The study will also try to select a recommended phase 3 dose of tazemetostat for further evaluation.
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
Epstein-Barr Virus (EBV) is the virus that causes mononucleosis, also known as mono. Almost all adults have had EBV. For most people, EBV never causes a health problem. However, when their immune system is not working properly (like people who have had a transplant and must be on medications that suppress their immune system), EBV can cause certain diseases…
Condition: Infectious Disease
Investigator: Sharon Mannheimer, MD
Status: Closed
We are looking for adult volunteers with presumed or confirmed monkeypox infections to help us see if tecovirimat (TPOXX) is a safe and effective treatment for monkeypox. Human Monkeypox Virus is currently the cause of an outbreak in the US and throughout the world, leading the World Health Organization to declare it a public health emergency of…
Condition: Cancer / Lymphoma
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of this study is to compare the usual treatment alone to using venetoclax plus the usual treatment. The addition of venetoclax to the usual treatment could shrink the cancer. But, it could also cause side effects. This study will help the study doctors find out if this different approach is better than the usual approach. To decide if it is…
Condition: Infectious Disease / HIV
Investigator: Michael Yin, MD
Status: Closed
Scientists are looking for ways to effectively clear HIV that rests in areas of the body where standard antiretroviral treatment (ART) is unable to reach. IL-15 superagonist (N-803) appears to reactivate HIV that is asleep and is also thought to increase the body's natural immune response to HIV. Broadly neutralizing antibodies (bNAbs), such as 10-1074…
Condition: Infectious Disease / HIV
Investigator: Michael Yin, MD
Status: Closed
This research study is being conducted to see if HIV antiretroviral medicines that you are taking continue to work well in transgender women and other individuals identifying as female or transfeminine, but with male sex assigned at birth (referred to as transgender) when taken with feminizing hormone therapy (FHT), also known in this study as estradiol.…
Condition: Infectious Disease / HIV
Investigator: Andrea Norcini Pala, PhD
Status: Closed
We are doing this research study to learn more about the lived experiences of discrimination and oppression based on race, sexual orientation, and HIV-status among Black men who have sex with men and live with HIV. We are interested in understanding how these experiences influence antiretroviral therapy use. Black men who have sex with men are heavily…
Condition: Infectious Disease
Investigator: Sharon Mannheimer, MD
Status: Closed
We are looking for adult volunteers to help us see if the FDA-approved Bexsero meningitis B vaccine can prevent people from getting gonorrhea infections. There are over 580,000 cases of gonorrhea diagnosed annually in the United States. Gonorrhea infections can significantly affect short and long-term reproductive health and contribute to increasing HIV…
Condition: Infectious Disease / HIV
Investigator: Marcus Pereira, MD, MPH
Status: Closed
The primary objective of this study is to determine if an HIV-infected donor liver (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications. This study will evaluate if receiving a liver transplant from an HIV-infected deceased liver donor is safe with regards to survival and major transplant-related and HIV-related…
Condition: Infectious Disease
Investigator: Melissa Stockwell, MD, MPH
Status: Closed
We are seeking volunteers who have been recently diagnosed with influenza virus infection by either rapid diagnostic assay or RT-PCR in the last 7 days, and live in a household with at least one other person. The study, also known as RVTN Flu will be looking at household transmission of influenza. Once someone and their household contacts are enrolled,…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Closed
The purpose of this study is to compare the usual treatment alone to using tazemetostat or zanubrutinib plus the usual treatment for patients with relapsed or refractory large B-cell lymphoma (LBCL). Relapsed means the LBCL has returned after it responded to treatment. Refractory means the LBCL did not respond to earlier treatment. The addition of…
Condition: Cancer / Lymphoma
Investigator: Fabio Iwamoto, MD
Status: Closed
In this research study, we are looking to see how safe and effective the combination of pembrolizumab, ibrutinib and rituximab is in your type of cancer. The FDA (the U.S. Food and Drug Administration) has not approved pembrolizumab, ibrutinib or rituximab for your specific disease but these have been approved for other uses including other types of non-…
Condition: Infectious Disease / HIV
Investigator: Michael Yin, MD
Status: Closed
We are doing a research study to find out if Long-Acting Injectable anti-HIV medications will be more successful than standard pills for people who have a hard time taking their HIV pills. If you are over the age of 18 years old, have been prescribed HIV medications but have had difficulty getting undetectable viral load (when the levels of virus in the…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
TAK-007 is being developed as a possible treatment for Lymphoma. TAK-007 is a cell therapy, which means that it consists of live cells that have been modified to help your body to fight Lymphoma. The use of TAK-007 in this study is experimental. Fresh (unfrozen) CAR NK cells, similar to TAK-007, are being tested in another study. In this study, frozen TAK-…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
You are being invited to take part in a research study that includes studying an experimental treatment named axicabtagene ciloleucel, referred to as axi-cel. The experimental treatment would involve removing some of your immune cells, genetically engineering those cells to identify cancer, receiving additional therapy while you wait for those cells to be…
Condition: Infectious Disease / HIV
Investigator: Jessica Justman, MD
Status: Closed
Pre-exposure prophylaxis, or PrEP, is the term used for medications that reduce the risk of getting HIV. There are approved medications that can be taken daily to prevent HIV infection. We are studying a PrEP medication that is a pill that can be taken once a month. It is being compared to an approved PrEP pill that is taken once daily. All women who take…
Condition: Infectious Disease / HIV
Investigator: Rebecca Schnall, PhD, RN
Status: Closed
Are you living with HIV? Are you 18 years or older? Do you own a smartphone? Are you interested in learning more about your health? We are conducting a study at Columbia University to learn more about how a phone app and sessions with a community health worker can help people living with HIV improve their health. You may receive up to $90 for your…
Condition: Blood Disorders / Amyloidosis
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of the study is to determine if the drug, CAEL-101 in combination with plasma cell treatment improves overall survival for patients who are diagnosed with stage 3b of AL amyloidosis. Patients who participate in this study will receive CAEL-101 as well as plasma cell treatment or Placebo as well as plasma cell treatment to compare the effects.
Condition: Infectious Disease
Investigator: Melissa Stockwell, MD, MPH
Status: Closed
The purpose of this study is to assess the effectiveness of influenza and SARS-CoV-2 vaccines for preventing transmission of infections in households. We are seeking volunteers who have been recently diagnosed with COVID-19 or Influenza virus infection by either rapid diagnostic assay or RT-PCR in the last 7 days and live in a household with at least one…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to find the highest dose of STK-009 that is safe in combination with a dose of SYNCAR-001 and to learn what side effects are experienced in people with certain lymphomas or leukemias. This study will also evaluate how much SYNCAR-001 and STK-009 is in your blood at various times, whether your immune system becomes activated,…
Condition: Infectious Disease
Investigator: Jason Zucker, MD
Status: Closed
Some things about the recent mpox outbreak were different from past, smaller mpox outbreaks. That means not enough is known about how certain health issues related to mpox might continue to affect some patients months later. To understand this, researchers also need to compare some feelings, well-being, and behaviors of persons who had mpox with those of…
Condition: Infectious Disease / HIV
Investigator: Michael Yin, MD
Status: Closed
Weight gain after starting antiretroviral therapy (ART) is common, but recent studies have found that some people living with HIV (PLWH) who are taking an integrase strand transfer inhibitor (INSTI) combined with tenofovir alafenamide/emtricitabine (TAF/FTC) or tenofovir alafenamide/lamivudine (TAF/3TC) may gain more weight than people taking other drug…
Condition: Infectious Disease / HIV
Investigator: Rebecca Schnall, PhD, RN
Status: Closed
Interested in quitting smoking? Help researchers at Columbia University School of Nursing test an intervention to help people living with HIV quit smoking cigarettes! To be eligible you must be 18 years or older, be a person living with HIV, be a current smoker, be interested in quitting smoking within the next 30 days, and owns a smartphone (Android). You…
Condition: Infectious Disease / HIV
Investigator: Michael Yin, MD
Status: Closed
The study is exploring the impact of gender, age, HIV infection, and menopausal status on dental health. The study is open to men and women, ages 35-70.
Condition: Infectious Disease / HIV
Investigator: Sunil Wadhwa, DDS, PhD
Status: Closed
The study is looking for postmenopausal women between the ages of 35-70 years that have moderate periodontitis for a 1 year-long study which provides free dental cleaning. There are a total of 5 study visits, each one about 2 hours long, and each study visit provides you with $50, for a total of $250.
Condition: Infectious Disease
Investigator: Magdalena Sobieszczyk, MD
Status: Closed
The main purpose of this study is to evaluate a Respiratory Syncytial Virus vaccine (RSVpreF for short). Respiratory Syncytial Virus, called RSV, is a common type of virus that is a major cause of respiratory infection in all ages, and can result in severe illness in those with health conditions that put them at increased risk of severe RSV and…
Condition: Cancer / Lymphoma
Investigator: Andrew Lipsky, MD
Status: Closed
This research study is being done to test the effectiveness and safety of an investigational treatment called LOXO-305. LOXO-305 is an investigational (or experimental) drug that may treat certain cancers like leukemia and lymphomas, including, mantle cell lymphoma (MCL). These cancers are dependent on or addicted to a protein made by the cancers called BTK…
Condition: Blood Disorders / Amyloidosis
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of the study is to determine if the drug, CAEL-101 in combination with plasma cell treatment improves overall survival for patients who are diagnosed with stage 3a of amyloid light chain (AL) amyloidosis. Patients who participate in this study will receive CAEL-101 as well as plasma cell treatment or Placebo as well as plasma cell treatment to…
Condition: Infectious Disease / HIV
Investigator: Jessica Justman, MD
Status: Closed
The purpose of this study is to understand if a smartphone app, SmartPrEP, will help promote HIV self-testing and PrEP adherence among cisgender and transgender women over a twelve-month period. We will help you to download the app on your phone and provide you with HIV self-test kits and PrEP (if not already taking PrEP) in order to understand if the…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR19B to treat certain types of cancers. PBCAR19B is a new investigational treatment for certain types of cancer of the blood, such as leukemia and lymphoma. It is made from a type of blood cells known as T cells. The T cells in PBCAR19B came from healthy…
Condition: Infectious Disease / HIV
Investigator: Rebecca Schnall, PhD, RN
Status: Closed
****CHAMPS Study for People Living with HIV Residing in NYC Area**** Are you living with HIV? Are you 18 years or older? Do you own a smartphone? Are you interested in learning more about your health? We are conducting a study at Columbia University to learn more about how a phone app and sessions with a community health worker can help people living with…
Condition: Cancer / Lymphoma
Investigator: Barbara Pro, MD
Status: Closed
The main purpose of this research study is to determine if the study drug CPO107 can be used safely in participants who have been diagnosed with non-Hodgkins lymphoma (NHL) and have failed at least two prior conventional anti-cancer drugs. Other purposes of the study are to monitor how the study drug is distributed and broken down inside the body. All…
Condition: Infectious Disease / HIV
Investigator: Michael Yin, MD
Status: Closed
This study is looking at hepatitis B virus (HBV) vaccination in adults 18 to 70 years of age living with HIV around the world. Hepatitis B is a serious viral infection that affects the liver and is transmitted through blood and body fluids. A vaccine (a shot of medicine given through a needle) can prevent HBV, but there is no cure. A new vaccine approved by…
Condition: Infectious Disease / HIV
Investigator: Julie Franks, PhD
Status: Closed
We are conducting a study to see if offering pre-exposure prophylaxis (PrEP) together with another health service that many transgender women use or would like to use, gender-affirming hormone therapy (GAHT), improves HIV-related outcomes, as compared to offering PrEP and referring study participants to get GAHT at area health providers. This study is for…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Closed
This study is being done to answer the following question: If we add the study drug nivolumab to standard chemotherapy will it extend your time without disease more than or less than if we add the study drug brentuximab vedotin to standard chemotherapy? We will also compare any side effects you may have and your well-being when you take the study drugs and…
Condition: Infectious Disease / HIV
Investigator: Rebecca Schnall, PhD, RN
Status: Closed
The mLab study at Columbia University is looking for cisgender men or trans women who are 18-29 years old and have sex with guys. Eligible individuals can earn up to $170 by participating in the online study and completing 3 surveys over the course of 1 year. Contact us if you are interested! Text/Call: 347-743-0104
Condition: Infectious Disease
Investigator: Ran Reshef, MD
Status: Closed
The purpose of the study is to: 1. Assess the safety of tabelecleucel. This will include looking at what adverse events (sometimes called side effects) occur and how often they occur. 2. Assess the effects of tabelecleucel on your Epstein-barr Virus (EBV) disease.
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to evaluate the safety and effectiveness of an antibody drug (STI-6129) in patients with AL amyloidosis that has returned or has not responded to treatment (relapsed/refractory). The study drug (STI-6129) will be given in 3 injections through a needle, into a vein as an intravenous (IV), with 21 days between each injection.
Condition: Infectious Disease / Lyme Disease
Investigator: Brian Fallon, MD
Status: Closed
Are you suffering from chronic fatigue that began after you were diagnosed and treated with antibiotics for Lyme Disease? This new treatment research study investigates whether disulfiram, commonly known as "Antabuse", has the potential to be used as a treatment option for patients experiencing chronic post-treatment Lyme symptoms. This well-known…
Condition: Infectious Disease / HIV
Investigator: Michael Yin, MD
Status: Closed
Did you know that people living with HIV are 50-100% more likely to develop heart disease (including heart attack and stroke) than people without HIV? And did you know that women with HIV are 3 times more likely to have a heart attack than women without HIV? Heart disease in HIV-infected people is a big deal. We are doing a study to test if a daily dose of…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Closed
The purpose of this study is to compare the combination of brentuximab vedotin and nivolumab to the combination of brentuximab vedotin, nivolumab, and ipilimumab. Both brentuximab vedotin and nivolumab are FDA-approved as single drugs for patients who have relapsed or refractory Hodgkins lymphoma. The combination of these drugs together, and with ipilimumab…
Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
This is a research study to test the effectiveness of NM-IL-12 an experimental drug, in combination with low dose Total Skin Electron Beam Therapy (TSEBT) for treatment of Cutaneous T Cell Lymphoma. The study will enroll 10 subjects age 18 years and older.Treatment will consist of 3 weeks of TSEBT, and up to 27 weeks of NM-IL-12 treatment starting from day…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a research study for subjects that have been previously treated for systemic light chain (AL)amyloidosis (a disease in which abnormal protein deposits can damage organs and tissues in your body) and nowrequire further treatment. The main purpose of this study is to evaluate the safety and determine the maximum tolerated dose of aninvestigational new…
Condition: Infectious Disease
Investigator: Marcus Pereira, MD, MPH
Status: Closed
The purpose of this research is to find out whether an experimental drug called maribivar is safe, and whether it is more effective than the medications we usually use to treat resistant CMV infections. Half of the people who choose to be part of this research study will be given maribivar, and half will be treated according to their physicians usual…
Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
This is a phase 2 study to determine the efficacy and safety of Naloxone HCL Lotion 0.5% for the treatment of mycosis fungoides (MF) type of cutaneous T-cell lymphoma (CTCL). Selected subjects will have the study drug applied to determine its effect on reducing itchiness and any potential side effects. Naloxone has previously been approved for direct blood…
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Closed
We are testing two antibodies directed against HIV virus. The human body uses antibodies as one way to help fight infection.The antibodies are called VRC01LS and VRC07-523LS and they are given by IV infusion. Each participant will receive one dose by infusion. The main purpose of this study is to see if these two antibodies are safe and how a participants…
Condition: Cancer / Lymphoma
Investigator: Nobuko Hijiya, MD
Status: Closed
This is a 2-part, multicenter study of a study drug in pediatric and young adult patients with mature B-cell non-Hodgkin Lymphoma which has come back or has not responded to the standard therapy. The study treatment is considered an experimental because the study drug is not approved by the United States (US) Food and Drug Administration (FDA) for treating…
Condition: Cancer / Lymphoma
Investigator: Owen O'Connor, MD, PhD
Status: Closed
This study will test the standard R-CHOP21 against R-CHOP21 plus lenalidomide. The purpose is to see whether adding lenalidomide works better and is as safe as R-CHOP by itself. This study is only for patients with ABC type DLBCL who have not yet been treated. Lenalidomide is not approved for use in DLBCL. Its use in this disease is experimental. In this…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The study is being done to see if the combination of bendamustine and dexamethasone will help people with amyloidosis that has returned after standard treatment. Bendamustine is currently approved by the Food and Drug Administration (FDA) for treatment of chronic lymphocytic leukemia (CLL) and is under clinical development in the United States for the…
Condition: Infectious Disease / HIV
Investigator: Jennifer Elliott, PhD
Status: Closed
NOTE: YOU MUST HAVE HIV AND HAVE EVER HAD HEPATITIS C TO BE ELIGIBLE FOR THIS STUDY!! ............... For individuals who have both HIV and Hepatitis C virus (HCV), heavy drinking poses serious risks to their health. We do not yet know which interventions are effective at helping individuals with HIV and HCV drink less. The goal of the study is to compare…
Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
This is a phase 3 clinical trial to determine the efficacy of topical SGX301 (synthetic hypericin) in combination with visible light therapy on cutaneous T-cell lymphoma (CTCL). Selected subjects can participate in 3 cycles each consisting of a 6 week treatment period where a chosen lesion will be treated with the study ointment (twice a week) followed by…
Condition: Blood Disorders / Amyloidosis
Investigator: Thomas Brannagan, MD
Status: Closed
HELIOS-A is a global Phase 3 randomized, open-label study designed to evaluate the safety and efficacy of ALN-TTRSC02 in adult patients with hATTR amyloidosis experiencing neurologic symptoms brought on by the disease. The study will also evaluate any changes in quality of life experienced by study participants. ALN-TTRSC02 utilizes the mechanism of RNA…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
The main purpose of this research study is to determine if the experimental treatment, axicabtagene ciloleucel in combination with utomilumab, is safe and effective in treating individuals with Large B-cell Lymphoma. Axicabtagene ciloleucel is manufactured using your own blood cells. Utomilumab is a molecule (protein) which interacts with a specific region…
Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
The purpose of this study is to better understand the use of Valchlor in clinical practice. Other goals include describing the demographic and clinical characteristics of disease and health outcomes of patients treated with Valchlor. Participating in this study will not influence the usual care you receive from your doctor.
Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
You are being asked to participate in a research study because you have Cutaneous T-Cell Lymphoma/Mycosis Fungoides, and one of your symptoms is itching. This study is being done to assess the efficacy and safety of Naloxone HCL Lotion 0.5% compared to Vehicle Lotion for the treatment of itching in patients with mycosis fungoides (MF) which is a type of…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to test for any good and bad effects of the study drug called isatuximab. Isatuximab may or may not improve your AL amyloidosis, but it could also cause side effects. Isatuximab is not approved by the Food and Drug Administration (FDA). Isatuximab has been shown to have good effects in some patients with recurring multiple…
Condition: Infectious Disease / HIV
Investigator: Rebecca Schnall, PhD, RN
Status: Closed
The Wellness Study is a 6-month study looking at how a phone app, a fitness tracker, and a pill dispenser can help people living with HIV monitor and improve their health by tracking their fitness and helping them remember to take their medication. You may receive up to $200.00 for your participation.
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
The main purpose of this research study is to determine if the experimental product, KTE-C19, when administered after a 3 day course of chemotherapy, is safe and effective in treating relapsed or refractory (r/r) indolent non-Hodgkin B-cell lymphoma (iNHL). KTE-C19 is made from white blood cells that are removed from the individual. A virus (retrovirus) is…
Condition: Cancer / Lymphoma
Investigator: Ahmed Sawas, MD
Status: Closed
The purpose of this study is to see if study drug IMO-8400 is safe and effective in the treatment of patientswith relapsed or refractory Diffuse Large B-Cell Lymphoma following conventional treatment.Examples of conventional treatment are radiotherapy, immunotherapy, chemotherapy, orradioimmunotherapy. Patients are scheduled to participate in this study…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to find out if the experimental combination of lenzilumab (an antibody that blocks the cytokine GM-CSF) and axicabtagene ciloleucel (which is identical to the FDA-approved CAR-T cell product YESCARTA) helps in protecting patients from side effects of axicabtagene ciloleucel. While axicabtagene ciloleucel has been approved by the…
Condition: Cancer / Lymphoma
Investigator: Naiyer Rizvi, MD
Status: Closed
This is the first study in humans for an investigational drug called CX-072. CX-072 is a Probody therapeutic directed against PD-L1 (programmed cell death ligand 1). Probody therapeutics are created from antibodies.
Condition: Blood Disorders / Amyloidosis
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of this study is to see if daratumumab when given with three other drugs cyclophosphamide, bortezomib (VELCADE) and dexamethasone is useful for treating patients with Amyloid light chain Amyloidosis (also known as AL Amyloidosis). The study will look at what happens (both good and bad) when daratumumab is given with these three drugs compared to…
Condition: Infectious Disease / Lyme Disease
Investigator: Brian Fallon, MD
Status: Closed
The CDC estimates that 10-20% of patients with Lyme disease will go on to have chronic symptoms despite having had appropriate treatment, a condition known as Post-Treatment Lyme Disease Syndrome (PTLDS). While there is currently no known cure, various therapies are being investigated. One promising approach is the practice of meditation and yoga which have…
Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
The purpose of the Main study is to test the overall effects of E7777 on you and your illness. It is not known what effect E7777 will have on your illness or what the side effects will be. This study will look at the effect E7777 has on your body and your disease. It will also look at how your body absorbs, distributes, breaks down, and gets rid of the…
Condition: Cancer / Lymphoma
Investigator: Ahmed Sawas, MD
Status: Closed
The purpose of this study is to determine a safe dose by testingthe investigational product, AGS67E at different dose levels. Secondly, to test what effects, good and/or bad, it has on subjects with refractory or relapsed non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL) or hairy cell leukemia (HCL). We will also…
Condition: Cancer / Lymphoma
Investigator: Markus Mapara, MD
Status: Closed
The purpose of this study is to study the impact of stem cell dose on outcome after autologous transplant. An autologous transplant is infusion of your own bone marrow cells (stem cells) following a high-dose of chemotherapy. Autologous transplant is the standard treatment for relapsed Diffuse Large B-Cell Lymphoma (DLBCL) or DLBCL that did not respond to…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to evaluate whether study drug NEOD001 will improve survival in subjects with AL amyloidosis and/or increase the interval of time that they can go without requiring hospitalization for problems with their hearts. This study will also evaluate whether NEOD001 improves the function of subjects' organs that have been affected…
Condition: Infectious Disease
Investigator: Marcus Pereira, MD, MPH
Status: Closed
This research study for people who have tested positive for cytomegalovirus (CMV) after receiving a solid-organ transplant or stem cell transplant. This is a non-interventional study. This study involves the use of an investigational test called the Aptima CMV Quantification Diagnostic Assay (Aptima CMV Quant Assay) to determine the levels of CMV in your…
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Closed
HVTN 108 is an HIV vaccine study for 18-50 year old and HIV-negative people. We would like the test vaccine to teach your immune system to defend against HIV in a manner that is safe and well-tolerated. We will ask that all participants prevent HIV as best as possible and reduce risk of getting HIV. We will ask you to come to the clinic 12 times over 12…
Condition: Infectious Disease / HIV
Investigator: Alex Carballo-Dieguez, MD
Status: Closed
This study will help scientists to understand the best ways to recruit and engage a wide variety of people (HIV-positive and HIV-negative) in HIV-related studies, using online recruitment methods. In this study you will be asked about topics including your preferences for specific attributes of online study recruitment ads and your use of the internet and…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Closed
The purpose of this study is to compare the effects of Ibrutinib when it is given Bendamustine (known as Treanda) and Rituximab (known as Rituxan) to Bendamustine and Rituximab alone. Inbrutinib is an experimental drug that blocks an enzyme that affects how the lymphocytes grow and survive. Blocking this enzyme is an important mechanism in killing cancer…
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Closed
Antibodies are one of the natural ways that our bodies fight or prevent infection. Were testing an antibody to find out if its safe, if it doesn't make people feel uncomfortable and to find out what may be the best dose if its given by IV infusion or sub-cutaneous injection. You cannot get HIV from the Bispecific Antibody. We'll ask you to…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to find out if the experimental product, axicabtagene ciloleucel, in combination with either rituximab or lenalidomide is safe and effective in treating lymphoma. Kite Pharma, Inc., (Kite) is the sponsor of this study. The sponsor is funding this research study and has also designed the trial. The sponsor is testing an…
Condition: Cancer / Lymphoma
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558). This study will see if treatment with nivolumab increases the chance you will have a positive response (complete or partial) in treating your primary central nervous system…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to find out if MLN9708 plus dexamethasone improves against systemic light chain amyloidosis better than the physicians choice chemotherapy treatment. Physicians choice chemotherapy treatment is a treatment regimen that is commonly used to treat amyloidosis patients. The study will also determine if MLN9708 plus dexamethasone can…
Condition: Infectious Disease
Investigator: Michael Yin, MD
Status: Closed
The purpose of this study is to test whether a study drug called Carbavance is safe and effective when compared to antibacterial medications that are commonly used for the treatment of serious infections. A screening will take 24 hours before the first dose of study drug. There are approximately 12 visits for this study.
Condition: Infectious Disease / HIV
Investigator: Rebecca Schnall, PhD, RN
Status: Closed
For People Living With HIV (PLWH) with HIV-Associated Non-AIDS (HANA) conditions such as cardiovascular disease or diabetes, the situation is complex given the added burden of coping with a secondary chronic illness and potential effects on treatment. How sex/gender differences in HIV symptom interpretation and management influence treatment success has not…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
Epstein-Barr Virus (EBV) is the virus that causes mononucleosis, also known as mono. Almost all adults have had EBV. For most people, EBV never causes a health problem. However, when their immune system is not working properly (people who have had a transplant and those who have immune disorders), EBV can cause certain diseases where cells grow abnormally…
Condition: Cancer / Lymphoma
Investigator: Ahmed Sawas, MD
Status: Closed
The purpose of this study is to gather information about the effectiveness and safety of as drug called brentuximab vedotin when given in combination with another drug called bendamustine for Hodgkin Lymphoma. The study will assess the safety profile of the combination treatment and determine what proportion of patients achieve a complete remission.…
Condition: Blood Disorders / Amyloidosis
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to evaluate the efficacy and safety of ION-682884 given for 24 months in patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN) also known as Familial Amyloid Polyneuropathy (FAP), and determine if it can help people with mild or moderate polyneuropathy. To be in this study you must have FAP and be…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE